DHA Protects Against Hepatic Steatosis by Activating Sirt1 in a High Fat Diet-Induced Nonalcoholic Fatty Liver Disease Mouse Model

References

• Brewis A, SturtzSreetharan C, Wutich A. Obesity stigma as a globalizing health challenge. Global Health. 2018;14:20. doi:10.1186/s12992-018-0337-x
   PubMed Web of Science ®Google Scholar
• Yki-Jarvinen H. Diagnosis of non-alcoholic fatty liver disease (NAFLD). Diabetologia. 2016;59:1104–1111. doi:10.1007/s00125-016-3944-1
   PubMed Web of Science ®Google Scholar
• Lim JS, Mietus-Snyder M, Valente A, Schwarz JM, Lustig RH. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol. 2010;7:251–264.
   PubMed Web of Science ®Google Scholar
• Bugianesi E, Moscatiello S, Ciaravella MF, Marchesini G. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des. 2010;16:1941–1951. doi:10.2174/138161210791208875
   PubMed Web of Science ®Google Scholar
• Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15:11–20. doi:10.1038/nrgastro.2017.109
   PubMed Web of Science ®Google Scholar
• Scalera A, Tarantino G. Could metabolic syndrome lead to hepatocarcinoma via non-alcoholic fatty liver disease? World J Gastroenterol. 2014;20:9217–9228. doi:10.3748/wjg.v20.i28.9217
   PubMed Web of Science ®Google Scholar
• Scorletti E, Byrne CD. Omega-3 fatty acids, hepatic lipid metabolism, and nonalcoholic fatty liver disease. Annu Rev Nutr. 2013;33:231–248. doi:10.1146/annurev-nutr-071812-161230
   PubMed Web of Science ®Google Scholar
• Shapiro H, Tehilla M, Attal-Singer J, Bruck R, Luzzatti R, Singer P. The therapeutic potential of long-chain omega-3 fatty acids in nonalcoholic fatty liver disease. Clin Nutr. 2011;30:6–19. doi:10.1016/j.clnu.2010.06.001
   PubMed Web of Science ®Google Scholar
• Jump DB, Depner CM, Tripathy S, Lytle KA. Potential for dietary omega-3 fatty acids to prevent nonalcoholic fatty liver disease and reduce the risk of primary liver cancer. Adv Nutr. 2015;6:694–702. doi:10.3945/an.115.009423
   PubMedGoogle Scholar
• Delarue J, Lalles JP. Nonalcoholic fatty liver disease: roles of the gut and the liver and metabolic modulation by some dietary factors and especially long-chain n-3 PUFA. Mol Nutr Food Res. 2016;60:147–159. doi:10.1002/mnfr.201500346
   PubMedGoogle Scholar
• Colak Y, Ozturk O, Senates E, et al. SIRT1 as a potential therapeutic target for treatment of nonalcoholic fatty liver disease. Med Sci Monit. 2011;17:HY5–9. doi:10.12659/MSM.881749
   PubMed Web of Science ®Google Scholar
• Rodgers JT, Lerin C, Haas W, Gygi SP, Spiegelman BM, Puigserver P. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature. 2005;434:113–118. doi:10.1038/nature03354
   PubMed Web of Science ®Google Scholar
• Luo X, Jia R, Yao Q, Xu Y, Luo Z, Wang N. Docosahexaenoic acid attenuates adipose tissue angiogenesis and insulin resistance in high fat diet-fed middle-aged mice via a sirt1-dependent mechanism. Mol Nutr Food Res. 2016;60:871–885. doi:10.1002/mnfr.201500714
   PubMedGoogle Scholar
• Luo X, Yang Y, Shen T, et al. Docosahexaenoic acid ameliorates palmitate-induced lipid accumulation and inflammation through repressing NLRC4 inflammasome activation in HepG2 cells. Nutr Metab (Lond). 2012;9:34. doi:10.1186/1743-7075-9-34
   PubMedGoogle Scholar
• Postic C, Girard J. Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest. 2008;118:829–838. doi:10.1172/JCI34275
   PubMed Web of Science ®Google Scholar
• Rosado CP, Rosa VHC, Martins BC, et al. Resistant starch from green banana (Musa sp.) attenuates non-alcoholic fat liver accumulation and increases short-chain fatty acids production in high-fat diet-induced obesity in mice. Int J Biol Macromol. 2019. doi:10.1016/j.ijbiomac.2019.09.199
   PubMedGoogle Scholar
• Miller CN, Morton HP, Cooney PT, et al. Acute exposure to high-fat diets increases hepatic expression of genes related to cell repair and remodeling in female rats. Nutr Res. 2014;34:85–93. doi:10.1016/j.nutres.2013.10.010
   PubMedGoogle Scholar
• Choi RY, Ham JR, Lee MK. Esculetin prevents non-alcoholic fatty liver in diabetic mice fed high-fat diet. Chem Biol Interact. 2016;260:13–21. doi:10.1016/j.cbi.2016.10.013
   PubMedGoogle Scholar
• Bagattin A, Hugendubler L, Mueller E. Transcriptional coactivator PGC-1alpha promotes peroxisomal remodeling and biogenesis. Proc Natl Acad Sci U S A. 2010;107:20376–20381. doi:10.1073/pnas.1009176107
   PubMed Web of Science ®Google Scholar
• Lee MS, Shin Y, Moon S, Kim S, Kim Y. Effects of eicosapentaenoic acid and docosahexaenoic acid on mitochondrial DNA replication and PGC-1alpha gene expression in C2C12 muscle cells. Prev Nutr Food Sci. 2016;21:317–322. doi:10.3746/pnf.2016.21.4.317
   PubMedGoogle Scholar
• Purushotham A, Schug TT, Xu Q, Surapureddi S, Guo X, Li X. Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009;9:327–338. doi:10.1016/j.cmet.2009.02.006
   PubMed Web of Science ®Google Scholar
• Pfluger PT, Herranz D, Velasco-Miguel S, Serrano M, Tschop MH. Sirt1 protects against high-fat diet-induced metabolic damage. Proc Natl Acad Sci U S A. 2008;105:9793–9798. doi:10.1073/pnas.0802917105
   PubMed Web of Science ®Google Scholar
• Vila L, Elias I, Roca C, et al. AAV8-mediated Sirt1 gene transfer to the liver prevents high carbohydrate diet-induced nonalcoholic fatty liver disease. Mol Ther Meth Clin Dev. 2014;1:14039. doi:10.1038/mtm.2014.39
   PubMedGoogle Scholar
• Feige JN, Lagouge M, Canto C, et al. Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab. 2008;8:347–358. doi:10.1016/j.cmet.2008.08.017
   PubMed Web of Science ®Google Scholar
• Yamazaki Y, Usui I, Kanatani Y, et al. Treatment with SRT1720, a SIRT1 activator, ameliorates fatty liver with reduced expression of lipogenic enzymes in MSG mice. Am J Physiol Endocrinol Metab. 2009;297:E1179–86. doi:10.1152/ajpendo.90997.2008
   PubMedGoogle Scholar
• Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007;22 Suppl 1:S20–7. doi:10.1111/j.1440-1746.2006.04640.x
   PubMedGoogle Scholar
• Nemoto S, Fergusson MM, Finkel T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}. J Biol Chem. 2005;280:16456–16460. doi:10.1074/jbc.M501485200
   PubMed Web of Science ®Google Scholar
• Xu F, Gao Z, Zhang J, et al. Lack of SIRT1 (Mammalian Sirtuin 1) activity leads to liver steatosis in the SIRT1± mice: a role of lipid mobilization and inflammation. Endocrinology. 2010;151:2504–2514. doi:10.1210/en.2009-1013
   PubMedGoogle Scholar
• Arrese M, Cabrera D, Kalergis AM, Feldstein AE. Innate immunity and inflammation in NAFLD/NASH. Dig Dis Sci. 2016;61:1294–1303. doi:10.1007/s10620-016-4049-x
   PubMed Web of Science ®Google Scholar
• Song NY, Na HK, Baek JH, Surh YJ. Docosahexaenoic acid inhibits insulin-induced activation of sterol regulatory-element binding protein 1 and cyclooxygenase-2 expression through upregulation of SIRT1 in human colon epithelial cells. Biochem Pharmacol. 2014;92:142–148. doi:10.1016/j.bcp.2014.08.030
   PubMed Web of Science ®Google Scholar
• Inoue T, Tanaka M, Masuda S, et al. Omega-3 polyunsaturated fatty acids suppress the inflammatory responses of lipopolysaccharide-stimulated mouse microglia by activating SIRT1 pathways. Biochim Biophys Acta. 2017;1862:552–560. doi:10.1016/j.bbalip.2017.02.010
   Google Scholar
• Zhu X, Liu Q, Wang M, et al. Activation of Sirt1 by resveratrol inhibits TNF-alpha induced inflammation in fibroblasts. PLoS One. 2011;6:e27081. doi:10.1371/journal.pone.0027081
   PubMed Web of Science ®Google Scholar
• Kauppinen A, Suuronen T, Ojala J, Kaarniranta K, Salminen A. Antagonistic crosstalk between NF-kappaB and SIRT1 in the regulation of inflammation and metabolic disorders. Cell Signal. 2013;25:1939–1948. doi:10.1016/j.cellsig.2013.06.007
   PubMed Web of Science ®Google Scholar
• Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J. 2004;23:2369–2380. doi:10.1038/sj.emboj.7600244
   PubMed Web of Science ®Google Scholar
• Jhou JP, Chen SJ, Huang HY, Lin WW, Huang DY, Tzeng SJ. Upregulation of FcgammaRIIB by resveratrol via NF-kappaB activation reduces B-cell numbers and ameliorates lupus. Exp Mol Med. 2017;49:e381. doi:10.1038/emm.2017.144
   PubMed Web of Science ®Google Scholar
• Chen LF, Williams SA, Mu Y, et al. NF-kappaB RelA phosphorylation regulates RelA acetylation. Mol Cell Biol. 2005;25:7966–7975. doi:10.1128/MCB.25.18.7966-7975.2005
   PubMed Web of Science ®Google Scholar